PDF(Pubmed)
Abstract：
UNASSIGNED: Adenocarcinoma of the rete testis (AORT) is an extremely rare and aggressive tumor with a poor prognosis. Its etiology and pathological characteristics have not been extensively studied, making accurate diagnosis and appropriate management challenging. AORT, an invasive testicular tumor with a mortality rate of 46%, treatment typically involves radical orchiectomy, retroperitoneal pelvic lymph node dissection (RPLND), adjuvant chemotherapy, and/or ongoing monitoring, but the response to conventional radiation and chemotherapy is limited. At present, no effective targeted therapy for AORT has been found.
UNASSIGNED: In this case report, we present the clinical scenario of a 50-year-old male patient initially diagnosed with a right testicular hydrocele, who subsequently underwent eversion of the parietal tunica vaginalis. Postoperative pathological analysis revealed metastatic clear cell renal cell carcinoma (ccRCC). PET/CT demonstrated findings suggestive of left renal upper pole carcinoma with involvement of the right scrotum, para-aortic region, bilateral iliac vessels, bilateral inguinal region, and multiple metastases. Sunitinib, a tyrosine kinase inhibitor, is commonly employed in the treatment of ccRCC. The patient underwent treatment with sunitinib for a duration of 20 months, resulting in the inactivation of multiple metastases. Following this, a radical orchiectomy was performed, and the postoperative pathology confirmed the presence of AORT. This article provides a comprehensive account of the patient\'s medical history, diagnostic process, treatment modalities, and subsequent follow-up observations.
UNASSIGNED: This case report highlights the successful use of targeted therapy with sunitinib in a patient with AORT. The patient showed a positive response to targeted therapy. This study not only provides a novel foundation for the treatment of AORT, but also offers valuable insights for future treatment strategies in managing this particular form of testicular cancer.
UNASSIGNED: In this case report, we present the clinical scenario of a 50-year-old male patient initially diagnosed with a right testicular hydrocele, who subsequently underwent eversion of the parietal tunica vaginalis. Postoperative pathological analysis revealed metastatic clear cell renal cell carcinoma (ccRCC). PET/CT demonstrated findings suggestive of left renal upper pole carcinoma with involvement of the right scrotum, para-aortic region, bilateral iliac vessels, bilateral inguinal region, and multiple metastases. Sunitinib, a tyrosine kinase inhibitor, is commonly employed in the treatment of ccRCC. The patient underwent treatment with sunitinib for a duration of 20 months, resulting in the inactivation of multiple metastases. Following this, a radical orchiectomy was performed, and the postoperative pathology confirmed the presence of AORT. This article provides a comprehensive account of the patient\'s medical history, diagnostic process, treatment modalities, and subsequent follow-up observations.
UNASSIGNED: This case report highlights the successful use of targeted therapy with sunitinib in a patient with AORT. The patient showed a positive response to targeted therapy. This study not only provides a novel foundation for the treatment of AORT, but also offers valuable insights for future treatment strategies in managing this particular form of testicular cancer.
摘要：
■睾丸网腺癌（AORT）是一种极为罕见的侵袭性肿瘤，预后不良。其病因和病理特点尚未得到广泛的研究,使准确的诊断和适当的管理具有挑战性。AORT,侵袭性睾丸肿瘤死亡率为46%,治疗通常包括根治性睾丸切除术，腹膜后盆腔淋巴结清扫术(RPLND),辅助化疗,和/或持续监测，但是对常规放疗和化疗的反应有限。目前,目前尚未发现有效的AORT靶向治疗.
■在此案例报告中，我们介绍了一名50岁男性患者的临床情况，最初诊断为右睾丸鞘膜积液，随后进行了阴道顶膜外翻。术后病理分析显示转移性透明细胞肾细胞癌（ccRCC）。PET/CT表现提示左肾上极癌累及右阴囊，主动脉旁区域,双侧髂血管,双侧腹股沟区，和多个转移。舒尼替尼，酪氨酸激酶抑制剂，通常用于治疗ccRCC。患者接受舒尼替尼治疗20个月，导致多个转移的失活。在此之后,进行了根治性睾丸切除术，术后病理证实存在AORT。本文对患者的病史进行了全面的描述，诊断过程,治疗方式，以及随后的后续观察。
■本病例报告重点介绍了舒尼替尼靶向治疗在一例AORT患者中的成功应用。患者对靶向治疗表现出阳性反应。本研究不仅为AORT的治疗提供了新的基础,但也为未来治疗这种特殊形式的睾丸癌的治疗策略提供了有价值的见解。
■在此案例报告中，我们介绍了一名50岁男性患者的临床情况，最初诊断为右睾丸鞘膜积液，随后进行了阴道顶膜外翻。术后病理分析显示转移性透明细胞肾细胞癌（ccRCC）。PET/CT表现提示左肾上极癌累及右阴囊，主动脉旁区域,双侧髂血管,双侧腹股沟区，和多个转移。舒尼替尼，酪氨酸激酶抑制剂，通常用于治疗ccRCC。患者接受舒尼替尼治疗20个月，导致多个转移的失活。在此之后,进行了根治性睾丸切除术，术后病理证实存在AORT。本文对患者的病史进行了全面的描述，诊断过程,治疗方式，以及随后的后续观察。
■本病例报告重点介绍了舒尼替尼靶向治疗在一例AORT患者中的成功应用。患者对靶向治疗表现出阳性反应。本研究不仅为AORT的治疗提供了新的基础,但也为未来治疗这种特殊形式的睾丸癌的治疗策略提供了有价值的见解。
